TDMS Study 96022-02 Pathology Tables
NTP Experiment-Test: 96022-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118) Date: 04/27/04
Route: GAVAGE Time: 14:02:07
CORE STUDY ALL GROUPS/FINAL #1
Facility: Battelle Columbus Laboratory
Chemical CAS #: TEFPCBMIX
Lock Date: 11/04/02
Cage Range: All
Reasons For Removal: 25018 Dosing Accident 25019 Moribund Sacrifice
25020 Natural Death 25021 Terminal Sacrifice
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 96022-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118) Date: 04/27/04
Route: GAVAGE Time: 14:02:07
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/
0 UG 10 UG 30 UG 100 UG 300 UG 500 UG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 98 86 98 86 98 86
Early Deaths
Moribund Sacrifice 21 20 21 23 43 44
Natural Death 5 14 8 13 10 22
Dosing Accident 2
Survivors
Terminal Sacrifice 27 17 24 15
Animals Examined Microscopically 53 51 53 53 53 66
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Small, Jejunum (53) (51) (53) (53) (53) (66)
Leiomyoma 1 (2%) 1 (2%)
Liver (53) (51) (53) (53) (53) (65)
Carcinoma, Metastatic, Pancreas 1 (2%)
Cholangiocarcinoma 4 (8%) 7 (13%) 7 (13%) 5 (8%)
Cholangiocarcinoma, Multiple 1 (2%) 12 (23%) 21 (40%) 7 (11%)
Cholangioma 1 (2%)
Hepatocellular Carcinoma 1 (2%)
Hepatocellular Adenoma 2 (4%) 1 (2%) 2 (4%) 7 (13%) 3 (5%)
Hepatocellular Adenoma, Multiple 2 (4%) 10 (19%) 2 (3%)
Hepatocholangioma 1 (2%) 1 (2%)
Hepatocholangioma, Multiple 1 (2%)
Oral Mucosa (53) (51) (53) (53) (53) (66)
Gingival, Squamous Cell Carcinoma 1 (2%) 1 (2%) 2 (4%) 4 (8%) 1 (2%)
Pancreas (53) (51) (53) (53) (53) (65)
Carcinoma 1 (2%)
Schwannoma Malignant, Metastatic, Uterus 1 (2%)
Acinus, Adenoma 1 (2%)
Salivary Glands (53) (51) (53) (52) (52) (66)
Schwannoma Malignant, Metastatic, Skin 1 (2%)
Stomach, Forestomach (53) (51) (53) (53) (53) (65)
Squamous Cell Carcinoma 1 (2%) 1 (2%)
Stomach, Glandular (53) (51) (53) (53) (53) (65)
Carcinoma 1 (2%)
Neuroendocrine Tumor, Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 96022-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118) Date: 04/27/04
Route: GAVAGE Time: 14:02:07
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/
0 UG 10 UG 30 UG 100 UG 300 UG 500 UG
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (53) (51) (53) (53) (53) (65)
Schwannoma Benign 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (53) (51) (53) (53) (53) (65)
Adenoma 1 (2%)
Carcinoma 1 (2%)
Subcapsular, Adenoma 1 (2%)
Adrenal Medulla (53) (51) (53) (53) (53) (64)
Pheochromocytoma Malignant 1 (2%)
Pheochromocytoma Benign 3 (6%) 3 (6%) 2 (4%) 1 (2%)
Islets, Pancreatic (53) (51) (53) (53) (53) (65)
Adenoma 1 (2%)
Carcinoma 1 (2%)
Pituitary Gland (53) (51) (52) (53) (53) (65)
Pars Distalis, Adenoma 30 (57%) 11 (22%) 16 (31%) 10 (19%)
Pars Distalis, Carcinoma 1 (2%)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (53) (51) (53) (52) (52) (66)
Bilateral, C-Cell, Adenoma 1 (2%) 1 (2%)
Bilateral, C-Cell, Carcinoma 1 (2%)
C-Cell, Adenoma 8 (15%) 5 (10%) 7 (13%) 8 (15%) 4 (8%) 1 (2%)
C-Cell, Carcinoma 3 (6%) 2 (4%) 2 (4%)
Follicular Cell, Adenoma 2 (4%) 2 (4%) 1 (2%)
Follicular Cell, Carcinoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (53) (51) (51) (52) (52) (66)
Carcinoma 1 (2%)
Ovary (53) (51) (53) (53) (53) (65)
Granulosa Cell Tumor Malignant 1 (2%)
Luteoma 1 (2%)
Periovarian Tissue, Carcinoma, Metastatic,
Page 3
NTP Experiment-Test: 96022-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118) Date: 04/27/04
Route: GAVAGE Time: 14:02:07
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/
0 UG 10 UG 30 UG 100 UG 300 UG 500 UG
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Pancreas 1 (2%)
Uterus (53) (51) (53) (53) (53) (66)
Carcinoma 1 (2%) 1 (2%) 1 (2%)
Carcinoma, Metastatic, Pancreas 1 (2%)
Fibrosarcoma 1 (2%)
Hemangiosarcoma 1 (2%)
Leiomyoma 1 (2%)
Polyp Stromal 8 (15%) 4 (8%) 6 (11%) 8 (15%) 6 (11%) 3 (5%)
Schwannoma Malignant 1 (2%)
Schwannoma Malignant, Metastatic, Vagina 1 (2%)
Squamous Cell Carcinoma 1 (2%)
Bilateral, Polyp Stromal 3 (6%) 2 (4%) 1 (2%) 1 (2%)
Cervix, Schwannoma Malignant 1 (2%)
Cervix, Schwannoma Malignant, Metastatic,
Vagina 1 (2%)
Vagina (2)
Schwannoma Malignant 1 (50%)
Schwannoma Malignant, Metastatic, Skin 1 (50%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (53) (51) (53) (53) (53) (66)
Lymph Node (28) (16) (16) (25) (20) (45)
Pancreatic, Carcinoma, Metastatic, Stomach,
Glandular 1 (4%)
Lymph Node, Mandibular (53) (51) (53) (52) (52) (66)
Schwannoma Malignant, Metastatic, Skin 1 (2%)
Spleen (53) (51) (53) (53) (53) (65)
Thymus (53) (51) (51) (51) (51) (59)
Thymoma Benign 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (53) (51) (53) (53) (53) (66)
Adenolipoma 1 (2%)
Adenoma 2 (4%) 1 (2%)
Carcinoma 4 (8%) 1 (2%) 3 (6%)
Carcinoma, Multiple 1 (2%) 1 (2%)
Fibroadenoma 27 (51%) 23 (45%) 21 (40%) 14 (26%) 4 (8%) 6 (9%)
Fibroadenoma, Multiple 15 (28%) 15 (29%) 15 (28%) 3 (6%)
Skin (53) (51) (53) (53) (53) (66)
Page 4
NTP Experiment-Test: 96022-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118) Date: 04/27/04
Route: GAVAGE Time: 14:02:07
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/
0 UG 10 UG 30 UG 100 UG 300 UG 500 UG
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM - cont
Basal Cell Adenoma 1 (2%)
Fibroma 1 (2%) 1 (2%) 1 (2%) 3 (6%)
Fibrosarcoma 1 (2%)
Schwannoma Malignant 1 (2%) 1 (2%)
Squamous Cell Papilloma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (1) (1)
Carcinoma, Metastatic, Pancreas 1 (100%)
Schwannoma Malignant, Metastatic, Uterus 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (53) (51) (53) (53) (53) (66)
Carcinoma, Metastatic, Pituitary Gland 1 (2%)
Carcinoma, Metastatic, Oral Mucosa 1 (2%)
Medulloblastoma Mal 1 (2%)
Cranial Nerve, Schwannoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (53) (51) (53) (53) (53) (66)
Carcinoma, Metastatic, Mammary Gland 1 (2%) 1 (2%)
Carcinoma, Metastatic, Pancreas 1 (2%)
Carcinoma, Metastatic, Thyroid Gland 1 (2%)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Cystic Keratinizing Epithelioma 6 (11%) 1 (2%) 6 (9%)
Cystic Keratinizing Epithelioma, Multiple 14 (26%) 48 (91%) 35 (53%)
Nose (53) (51) (53) (53) (53) (66)
Schwannoma Malignant, Metastatic, Brain 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (53) (51) (53) (53) (53) (66)
Carcinoma, Metastatic, Oral Mucosa 1 (2%)
____________________________________________________________________________________________________________________________________
Page 5
NTP Experiment-Test: 96022-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118) Date: 04/27/04
Route: GAVAGE Time: 14:02:07
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/
0 UG 10 UG 30 UG 100 UG 300 UG 500 UG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (53) (51) (53) (53) (53) (65)
Carcinoma, Metastatic, Pancreas 1 (2%)
Papilloma 1 (2%)
Renal Tubule, Adenoma 1 (2%)
Renal Tubule, Carcinoma 1 (2%)
Urinary Bladder (53) (51) (53) (53) (52) (66)
Schwannoma Malignant, Metastatic, Uterus 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(53) *(51) *(53) *(53) *(53) *(66)
Adenolipoma 1 (2%)
Leukemia Granulocytic 1 (2%)
Leukemia Mononuclear 1 (2%)
Lymphoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 96022-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118) Date: 04/27/04
Route: GAVAGE Time: 14:02:07
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/
0 UG 10 UG 30 UG 100 UG 300 UG 500 UG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 53 47 51 42 51 45
Total Primary Neoplasms 126 80 96 102 115 73
Total Animals with Benign Neoplasms 53 43 47 40 51 45
Total Benign Neoplasms 107 68 76 74 85 59
Total Animals with Malignant Neoplasms 16 12 18 21 28 14
Total Malignant Neoplasms 19 12 20 27 30 14
Total Animals with Metastatic Neoplasms 1 5 6 1
Total Metastatic Neoplasm 1 8 13 1
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1
Total Uncertain Neoplasms 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
NTP Experiment-Test: 96022-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118) Date: 04/27/04
Route: GAVAGE Time: 14:02:07
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 4000 NG/
500UG ST
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50
Early Deaths
Moribund Sacrifice 28
Natural Death 12
Survivors
Terminal Sacrifice 10
Animals Examined Microscopically 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Colon (50)
Intestine Large, Cecum (50)
Intestine Small, Duodenum (50)
Intestine Small, Jejunum (50)
Intestine Small, Ileum (50)
Liver (50)
Cholangiocarcinoma 7 (14%)
Cholangiocarcinoma, Multiple 12 (24%)
Hepatocellular Adenoma 1 (2%)
Hepatocholangioma 1 (2%)
Oral Mucosa (50)
Gingival, Squamous Cell Carcinoma 1 (2%)
Pancreas (50)
Salivary Glands (49)
Stomach, Forestomach (50)
Squamous Cell Papilloma 1 (2%)
Stomach, Glandular (50)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (50)
Heart (50)
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 96022-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118) Date: 04/27/04
Route: GAVAGE Time: 14:02:07
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 4000 NG/
500UG ST
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Thyroid Gland (49)
C-Cell, Adenoma 4 (8%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Uterus (50)
Polyp Stromal 7 (14%)
Bilateral, Polyp Stromal 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Lymph Node (22)
Lymph Node, Mandibular (49)
Lymph Node, Mesenteric (50)
Spleen (50)
Thymus (46)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50)
Carcinoma 1 (2%)
Fibroadenoma 11 (22%)
Fibroadenoma, Multiple 1 (2%)
Skin (50)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
Page 9
NTP Experiment-Test: 96022-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118) Date: 04/27/04
Route: GAVAGE Time: 14:02:07
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 4000 NG/
500UG ST
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50)
Cranial Nerve, Squamous Cell Carcinoma,
Metastatic, Oral Mucosa 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50)
Cystic Keratinizing Epithelioma 7 (14%)
Cystic Keratinizing Epithelioma, Multiple 5 (10%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
None
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50)
Urinary Bladder (50)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50)
Lymphoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 10
NTP Experiment-Test: 96022-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118) Date: 04/27/04
Route: GAVAGE Time: 14:02:07
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 4000 NG/
500UG ST
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 36
Total Primary Neoplasms 61
Total Animals with Benign Neoplasms 28
Total Benign Neoplasms 39
Total Animals with Malignant Neoplasms 20
Total Malignant Neoplasms 22
Total Animals with Metastatic Neoplasms 1
Total Metastatic Neoplasm 1
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 11
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------